Google
OABI Stock Price & Analysis — Omniab Inc. (Healthcare >> Biotechnology)
OABI FAQ
What is OABI's ROE?
Omniab Inc. reports a Return on Equity (ROE) of -20.67%.
What is OABI's dividend yield?
Omniab Inc. offers a dividend yield of 0.00%.
What is OABI's Quality Score?
Our AI rates OABI's overall financial quality at 38 out of 100, based on profitability, growth, debt and earnings stability.
Is now a good time to buy OABI?
Our AI Timing Score for OABI is 26 out of 100, indicating the relative attractiveness of buying at the current price using technical and momentum signals.
Which sector does OABI belong to?
Omniab Inc. is classified under the Healthcare >> Biotechnology sector on the NASDAQ exchange
OABI AI Analysis Summary
Our AI summary for OABI: Omniab Inc. (NASDAQ), Healthcare >> Biotechnology sector. The stock currently trades at a P/E of 0.00, ROE of -20.67%, a dividend yield of 0.00%. Its financial Quality Score stands at 38/100 — fundamentals below the market average. The AI Timing Score is 26/100 — most technical signals do not support an entry at this point. All scores are recomputed automatically after each market close from official exchange data. This is systematically generated analysis, not personalized investment advice.
|
USD 1.96
Price
-0.02
(-1.01%)
Day Change
|
|
|---|
OABI, the overall quality is not good ( Quality = 38) and the timing to buy is ...(Sign In to See)...
Loading chart...
- Signal
- UNDERPERFORM
- Signal Description
- Company financial health is Not Good
- Reason
-
ROE is relatively low.
ROA is relatively low.
Historical ROE is relatively low
Negative growth of ROE in the last year.
ROA is too relatively low compare to ROE
Growth of ROA was below our criteria in the last year.
Net profit margin is relatively low.
Historical net profit margin is relatively low.
88 Sign in
TIMING
- Signal
- OUTPERFORM
- Signal Descri...
- Good
- Reason
- Momentum indicators aligned on the daily timeframe
In details, quality factors are not good , financial health is not good , and ability to make profit is ok , ...
| Quality Factors |
|
48% |
| In Recommendations? | Not in any sections |
| Select Rate | 0.00 From 30 days period |
| Watch Rate | 0.00 From 30 days period |
| News Score | 92 |
| Magic Formula Rank by ROA |
N/A
|
| Magic Formula Rank by ROE |
N/A
|
| Magic Formula Rank by ROIC |
N/A
|
| Price | 1.96 |
| PBV / Sector |
1.09 / 44,219.29
GREAT
|
| Earning Per Share | -0.37 |
| PE / Sector |
N/A / 19.28
|
| PEG or PE/Growth / Sector |
N/A / 1.23
|
| Average 1M Daily Value |
0.90 M
GREAT
|
| Average 1W Daily Value |
0.51 M
GREAT
|
| Timing Factors |
|
28% |
| Financial Health |
|
45% |
| Ability to Make Profit |
|
60% |
| Return to Investors |
|
4% |
| Registration Details |
| Analyze Date | 2026-08-04 08:01:56 |
| Symbol | OABI |
| Name | OMNIAB INC. |
| Sector | Healthcare >> Biotechnology |
| Market | NASDAQ |
| Listed Shares | 144.97 M |
| Par Value | N/A |
| Calculated From | Quarter |
| Sign | N/A |
| Market Cap (M.USD) / Sector Average | 287.05 / 9,645.64 |
| News, Concensus, ... |
| Estimation Consensus | See at WSJ.com |
| Full details | See at WSJ.com |
| Chart | See in Chart feature |
| News | See at Yahoo Finance |
Address: 5980 Horton Street, EmeryVille, CA, United States, 94608
Phone: 510 250 7800
Website: https://www.omniab.com
Employees: 89
Sector: Healthcare >> Biotechnology
Description: OmniAb, Inc., a biotechnology company, licenses discovery research technology to pharmaceutical and biotech companies, and academic institutions to enable the discovery of therapeutics in the United States, Europe, Japan, China, and Canada. The company's technology platform creates and screens diverse antibody repertoires to identify optimal antibodies and other target-binding proteins for partners' drug development efforts. Its OmniAb platform's Biological Intelligence powers the immune systems of its proprietary and engineered transgenic animals to create optimized antibody candidates for human therapeutics. The company offers animal-based technologies include OmniRat, OmniChicken, and OmniMouse, which have been genetically modified to generate antibodies with human sequences; OmniFlic, a bispecific rat and OmniClic, a bispecific chicken are designed for discovery of bispecific antibody applications; OmniTaur, which provides cow-inspired antibodies with unique structural characteristics for challenging targets; OmnidAb, an in vivo platform for the discovery of single-domain antibodies based upon a human VH scaffold; and OmniDeep, a suite of in silico, an artificial intelligence (AI) and machine learning tools for therapeutic discovery and optimization through various technologies and capabilities. It has an agreement with mAbsolve Ltd. for its Fc-silencing platform technology to incorporate the STR technology into antibodies that have been generated using OmniAb's antibody discovery platform. OmniAb, Inc. was founded in 2012 and is headquartered in Emeryville, California.
Analyst Ratings & Target Price
ME vs SECTOR Healthcare >> Biotechnology
Click a bubble to view stock details · Bubble size represents market capitalization share
Top Related Stocks
Stocks in the Same Sector
Healthcare › BiotechnologyAnalysed on the same criteria, ordered by market cap